Welcome to our dedicated page for NeOnc Technologies Holdings news (Ticker: NTHI), a resource for investors and traders seeking the latest updates and insights on NeOnc Technologies Holdings stock.
NeOnc Technologies Holdings, Inc. (NTHI) is a clinical-stage biotechnology leader focused on central nervous system therapeutics and advanced drug delivery systems. This page provides investors and industry observers with timely updates on clinical trial progress, regulatory developments, and strategic initiatives critical to evaluating the company's position in the CNS treatment market.
Access consolidated information on NTHI's proprietary NEO platform advancements, intellectual property milestones, and collaborative research partnerships. The resource covers essential updates including FDA designations, trial phase results, and executive commentary without speculative analysis.
Key content types include earnings communications, clinical trial status reports, patent filings, and leadership updates. All materials maintain compliance with financial disclosure regulations while emphasizing technological developments in blood-brain barrier penetration techniques.
Bookmark this page for streamlined tracking of NTHI's progress in addressing complex neurological conditions through its innovative therapeutic pipeline. Regular updates ensure stakeholders remain informed about developments that may influence long-term research trajectories and market positioning.
NeOnc Technologies (NASDAQ: NTHI) reported Q3 2025 results and operational updates on Nov 14, 2025. Key items include a $50.0 million strategic partnership via NuroMENA with Quazar Investment, $2.5 million in NIH STTR grants, FDA authorization to proceed with a Phase II trial of NEO212, and completed Phase 2a topline enrollment for NEO100 with encouraging efficacy signals (21% response rate; 44% six-month PFS; 33% alive ≥18 months).
Q3 financials showed a $8.6 million net loss ($0.45/share) driven by higher G&A of $903k. Upcoming catalysts: final NEO212 Phase I dosing in Q4 2025, NEO100-01 topline data in May 2026, and near-term closing/funding of the $50M commitment.
NeOnc Technologies (Nasdaq: NTHI) announced completion of full patient enrollment in the NEO100-1 Phase 2a trial for recurrent IDH1-mutant high-grade glioma (WHO Grade III/IV) on Nov 13, 2025. The company expects a preliminary data readout from the fully enrolled cohort in approximately six months, in Q2 2026. The announcement follows previously reported positive interim data from a 24-patient cohort presented on Nov 12, 2025. Management highlighted NEO100’s intranasal delivery designed to bypass the blood-brain barrier and said the readout could further validate clinical potential and advance NeOnc’s CNS oncology strategy.
NeOnc Technologies (NASDAQ:NTHI) reported updated Phase 1/2a and compassionate-use data (cohort n=24) for intranasal NEO100 in recurrent WHO Grade III/IV IDH1‑mutant astrocytoma on Nov 12, 2025. Key outcomes: a 21% radiographic response rate (5/24) confirmed by contrast-enhanced and perfusion MRI, 44% PFS‑6 (6‑month progression‑free survival), and 33% alive ≥18 months (8/24). No significant toxicity was reported with prolonged intranasal dosing. The company frames these results as exceeding historical salvage-therapy benchmarks (<8% response; 21–31% PFS‑6) and potentially meaningful for durable disease control pending full enrollment and six‑month post‑enrollment readout.
NeOnc Technologies (Nasdaq: NTHI) will host an investor conference call and webcast on Wednesday, November 12, 2025 at 6:00 a.m. PT / 9:00 a.m. ET (prior to market open).
Management and independent Scientific Advisory Board members will present data updates from the ongoing Phase 1/2a NEO100-1 trial and compassionate use program, covering intranasal NEO100 (high-purity perillyl alcohol) in recurrent high-grade malignant glioma patients. Presentations will highlight MRI-based radiographic responses, progression-free survival (PFS), and overall survival (OS) trends observed to date. The live webcast will be available at https://investors.neonc.com.
NeOnc Technologies (NASDAQ: NTHI) announced on November 4, 2025 that Amir Heshmatpour has been appointed Chief Executive Officer, effective immediately, while continuing as Executive Chairman.
Founder Dr. Thomas Chen will transition from CEO to focus on Chief Medical Officer and Chief Scientific Officer roles and clinical development of the company’s multi-Phase 2 programs. Recent corporate milestones cited include a $50 million strategic partnership with Quazar Investment, establishment of a UAE subsidiary (NuroMENA), expansion of the Scientific Advisory Board, and a NEO™ platform protected by more than 179 worldwide patents.
NeOnc Technologies (NASDAQ:NTHI) announced that His Highness Sheikh Nahyan bin Zayed Al Nahyan will formally assume the role of Executive Chairman of NuroMENA, NeOnc's Middle East subsidiary, effective Oct. 28, 2025. Amir Heshmatpour will transition to Vice Chairman of NuroMENA. The move establishes a UAE–US partnership focused on advancing therapies for brain cancer and other CNS malignancies.
The release highlights expected strategic support from the influence and resources of a major sovereign wealth fund and frames the appointment as strengthening humanitarian and innovation efforts to accelerate development of NeOnc’s multi‑Phase 2 clinical programs.
NeOnc Technologies (NASDAQ: NTHI) announced that its wholly owned subsidiary NuroMENA signed a Master Services Agreement (MSA) with UAE-based contract research organization IROS, part of the M42 group, to support clinical development in the Middle East on October 9, 2025. The MSA grants NuroMENA access to Abu Dhabi’s health ecosystem, AI/technology and genomics capabilities to accelerate NeOnc’s Phase 2 CNS cancer programs.
Concurrently, NuroMENA expanded its board to add two Quazar Investment representatives, including CEO Waleed K. Al Ali and the Quazar chairman, joining existing directors Amir Heshmatpour, Dr. Ishwar K. Puri and Bader Al Monawer to oversee regional strategy.
NeOnc Technologies (NASDAQ:NTHI) announced that, after receiving required UAE tax and regulatory approvals, a previously signed definitive agreement with Abu Dhabi-based Quazar Investment for a $50 million strategic equity partnership is mandated to close no later than October 23, 2025. The deal centers on Abu Dhabi operating subsidiary NuroCure under NuroMENA Holdings, which was incorporated in the Abu Dhabi Global Market on August 6, 2025, satisfying closing contingencies. The partnership allocates $15 million specifically to Phase 2B clinical trials and UAE/MENA infrastructure development and aims to accelerate NeOnc’s pipeline, including NEO100 (multiple trials) and NEO212 programs, plus a pediatric NEO100-03 Phase 1 trial, in collaboration with Cleveland Clinic UAE.
NeOnc Technologies (NTHI), a clinical-stage biopharmaceutical company focused on CNS cancer therapies, has appointed Dr. David M. Ashley to its Scientific Advisory Board. Dr. Ashley serves as the Director of The Preston Robert Tisch Brain Tumor Center at Duke University and holds the position of Rory David Deutsch Distinguished Professor of Neuro-Oncology.
Dr. Ashley brings significant expertise in brain tumor immunology and epigenetics, with experience in both pediatric and adult brain cancers. His appointment is expected to strengthen NeOnc's pipeline, particularly the development of lead candidates NEO100™ and NEO212™. Since 2018, he has led one of North America's largest dedicated brain tumor centers, integrating clinical care, translational research, and education.
NeOnc Technologies (NTHI), a clinical-stage biopharmaceutical company focused on central nervous system (CNS) cancers, has appointed Dr. Alexandra M. Miller to its Scientific Advisory Board. Dr. Miller serves as Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health's Perlmutter Cancer Center.
Dr. Miller's expertise in liquid biopsy assays for CNS tumors and cerebrospinal fluid diagnostics will support NeOnc's clinical trials for NEO100™ and NEO212™. The appointment coincides with NeOnc's expansion of its global trial network into the Middle East and India, strengthening the company's position in brain cancer research.
FAQ
What is the current stock price of NeOnc Technologies Holdings (NTHI)?
What is the market cap of NeOnc Technologies Holdings (NTHI)?
